Cirius Therapeutics

Mitochondrial-target metabolic therapeutics

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
AzemiglitazoneNo recent activity
Phase 2
Mitochondrial pyruvate carrierSmall molecule
Type 2 Diabetes

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

4 November 2019Topline resultMSDC-0602K (azemiglitazone)Phase 2b EMMINENCE (NCT02784444) of MSDC-0602K in NASH missed its primary liver-histology endpoint
Global · Cirius Therapeutics · Source ↗

Financial reports

No financial reports recorded.